BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 29176760)

  • 1. Clostridium difficile flagellin FliC: Evaluation as adjuvant and use in a mucosal vaccine against Clostridium difficile.
    Bruxelle JF; Mizrahi A; Hoÿs S; Collignon A; Janoir C; Péchiné S
    PLoS One; 2017; 12(11):e0187212. PubMed ID: 29176760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection against Clostridium difficile infection in a hamster model by oral vaccination using flagellin FliC-loaded pectin beads.
    Bruxelle JF; Tsapis N; Hoys S; Collignon A; Janoir C; Fattal E; Péchiné S
    Vaccine; 2018 Sep; 36(40):6017-6021. PubMed ID: 30172633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenic properties of the surface layer precursor of Clostridium difficile and vaccination assays in animal models.
    Bruxelle JF; Mizrahi A; Hoys S; Collignon A; Janoir C; Péchiné S
    Anaerobe; 2016 Feb; 37():78-84. PubMed ID: 26505926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diminished intestinal colonization by Clostridium difficile and immune response in mice after mucosal immunization with surface proteins of Clostridium difficile.
    Péchiné S; Janoir C; Boureau H; Gleizes A; Tsapis N; Hoys S; Fattal E; Collignon A
    Vaccine; 2007 May; 25(20):3946-54. PubMed ID: 17433506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toll-like receptor 5-dependent immunogenicity and protective efficacy of a recombinant fusion protein vaccine containing the nontoxic domains of Clostridium difficile toxins A and B and Salmonella enterica serovar typhimurium flagellin in a mouse model of Clostridium difficile disease.
    Ghose C; Verhagen JM; Chen X; Yu J; Huang Y; Chenesseau O; Kelly CP; Ho DD
    Infect Immun; 2013 Jun; 81(6):2190-6. PubMed ID: 23545305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and protective efficacy of recombinant Clostridium difficile flagellar protein FliC.
    Ghose C; Eugenis I; Sun X; Edwards AN; McBride SM; Pride DT; Kelly CP; Ho DD
    Emerg Microbes Infect; 2016 Feb; 5(2):e8. PubMed ID: 26839147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variability of Clostridium difficile surface proteins and specific serum antibody response in patients with Clostridium difficile-associated disease.
    Péchiné S; Janoir C; Collignon A
    J Clin Microbiol; 2005 Oct; 43(10):5018-25. PubMed ID: 16207956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction and evaluation of the immune protection of a recombinant divalent protein composed of the MrpA from MR/P fimbriae and flagellin of Proteus mirabilis strain against urinary tract infection.
    Habibi M; Asadi Karam MR; Bouzari S
    Microb Pathog; 2018 Apr; 117():348-355. PubMed ID: 29452195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Active immunization of hamsters against Clostridium difficile infection using surface-layer protein.
    Ní Eidhin DB; O'Brien JB; McCabe MS; Athié-Morales V; Kelleher DP
    FEMS Immunol Med Microbiol; 2008 Mar; 52(2):207-18. PubMed ID: 18093141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic antibody responses induced by a two-component Clostridium difficile toxoid vaccine protect against C. difficile-associated disease in hamsters.
    Anosova NG; Brown AM; Li L; Liu N; Cole LE; Zhang J; Mehta H; Kleanthous H
    J Med Microbiol; 2013 Sep; 62(Pt 9):1394-1404. PubMed ID: 23518659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A heterologous prime-boost route of vaccination based on the truncated MrpH adhesin and adjuvant properties of the flagellin from Proteus mirabilis against urinary tract infections.
    Asadi Karam MR; Shirzad AM; Habibi M; Bouzari S
    Int Immunopharmacol; 2018 May; 58():40-47. PubMed ID: 29549718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters.
    Giannasca PJ; Zhang ZX; Lei WD; Boden JA; Giel MA; Monath TP; Thomas WD
    Infect Immun; 1999 Feb; 67(2):527-38. PubMed ID: 9916055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antigen-Specific Mucosal Immunity Regulates Development of Intestinal Bacteria-Mediated Diseases.
    Fujimoto K; Kawaguchi Y; Shimohigoshi M; Gotoh Y; Nakano Y; Usui Y; Hayashi T; Kimura Y; Uematsu M; Yamamoto T; Akeda Y; Rhee JH; Yuki Y; Ishii KJ; Crowe SE; Ernst PB; Kiyono H; Uematsu S
    Gastroenterology; 2019 Dec; 157(6):1530-1543.e4. PubMed ID: 31445037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of protective immunity against Streptococcus mutans colonization after mucosal immunization with attenuated Salmonella enterica serovar typhimurium expressing an S. mutans adhesin under the control of in vivo-inducible nirB promoter.
    Huang Y; Hajishengallis G; Michalek SM
    Infect Immun; 2001 Apr; 69(4):2154-61. PubMed ID: 11254570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of vaccine for Clostridium difficile infection using membrane fraction of nontoxigenic Clostridium difficile.
    Senoh M; Iwaki M; Yamamoto A; Kato H; Fukuda T; Shibayama K
    Microb Pathog; 2018 Oct; 123():42-46. PubMed ID: 29959036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clostridium difficile TxAC314 and SLP-36kDa enhance the immune response toward a co-administered antigen.
    Brun P; Scarpa M; Grillo A; Palù G; Mengoli C; Zecconi A; Spigaglia P; Mastrantonio P; Castagliuolo I
    J Med Microbiol; 2008 Jun; 57(Pt 6):725-731. PubMed ID: 18480329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of a Salmonella typhimurium aroA aroD vaccine expressing a nontoxic domain of Clostridium difficile toxin A.
    Ward SJ; Douce G; Figueiredo D; Dougan G; Wren BW
    Infect Immun; 1999 May; 67(5):2145-52. PubMed ID: 10225867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucosal immunization with purified flagellin from Salmonella induces systemic and mucosal immune responses in C3H/HeJ mice.
    Strindelius L; Filler M; Sjöholm I
    Vaccine; 2004 Sep; 22(27-28):3797-808. PubMed ID: 15315861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Chimeric Protein Vaccines Against
    Wang S; Wang Y; Cai Y; Kelly CP; Sun X
    Front Immunol; 2018; 9():2440. PubMed ID: 30405630
    [No Abstract]   [Full Text] [Related]  

  • 20. Use of recombinant flagellin in oil-in-water emulsions enhances hemagglutinin-specific mucosal IgA production and IL-17 secreting T cells against H5N1 avian influenza virus infection.
    Lai CH; Tang N; Jan JT; Huang MH; Lu CY; Chiang BL; Huang LM; Wu SC
    Vaccine; 2015 Aug; 33(35):4321-9. PubMed ID: 25858857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.